Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.
PLoS Med
October 2024
Harvard Medical School, Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Background: The interaction of CD40L and its receptor CD40 on activated T cells and B cells respectively control pro-inflammatory activation in the pathophysiology of autoimmunity and transplant rejection. Previous studies have implicated signaling pathways involving CD40L (interchangeably referred to as CD154), as well as adaptive and innate immune cell activation, in the induction of neuroinflammation in neurodegenerative diseases. This study aimed to assess the safety, tolerability, and impact on pro-inflammatory biomarker profiles of an anti CD40L antibody, tegoprubart, in individuals with amyotrophic lateral sclerosis (ALS).
View Article and Find Full Text PDFIndications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS).
Front Pharmacol
August 2024
The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Shandong, Jinan, China.
Background: Teriparatide is approved for osteoporosis. Post-marketing surveillance is critical given its widespread use.
Objective: To investigate adverse events (AEs) associated with teriparatide using the FAERS database, compare association strengths for key AEs, and explore potential applications to provide clinical reference.
Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.
Heliyon
July 2024
Dongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, The First Dongguan Affiliated Hospital, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, 523808, China.
Objective: Based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, we analyzed the signals of potential adverse events (AEs) of orlistat in the real world to provide a reference for its safe clinical use.
View Article and Find Full Text PDFCorrelation between bony structures of the posterior cranial fossa and the occurrence of hemifacial spasm.
Front Neurol
July 2024
Department of Neurosurgery, China-Japan Friendship Hospital, Beijing, China.
Objective: To quantitatively study the measurement data related to the bony posterior cranial fossa and explore the correlation between bony posterior cranial fossa morphology and the occurrence of hemifacial spasm.
Methods: A total of 50 patients with hemifacial spasm who attended the Department of Neurosurgery of China-Japan Friendship Hospital from October 2021 to February 2022 were included, and 60 patients with minor head trauma excluding skull fracture and intracranial abnormalities were included as controls. Cranial multilayer spiral CTs (MSCTs) were performed in both groups, and multiplanar reconstruction (MPR) was used as a postprocessing method to measure data related to the posterior cranial fossa in both groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!